Vectibix
Links shared publicly online about this topic
Updated Vectibix prescribing information - MPR
empr.com — “The FDA has approved revisions to the prescribing information of Vectibix (panitumumab), a human epidermal growth factor receptor (EGFr) inhibitor.” View full resource at empr.com
Most Recently Shared on July 20, 2009 at 3:43 pm By:
MPR News: Updated Vectibix prescribing information: The FDA has approved revisions to the prescribing i.. http://bit.ly/TMBRH
VECTIBIX (Panitumumab) drug information from MPR
empr.com — “VECTIBIX (Panitumumab) drug information for Cancer, colorectal, Neoplasms from MPR including side effects, drug interactions, dosing, contraindications and precautions.” View full resource at empr.com
Most Recently Shared on April 29, 2010 at 4:14 am By:
MPR News: VECTIBIX: Precautions: added information on KRAS mutations, increased toxicity with combination chemotherapy. http://bit.ly/cLd2O8
Article > NICE draft "no" to Erbitux, Avastin, Vectibix
pharmatimes.com — “Article > NICE draft "no" to Erbitux, Avastin, Vectibix” View full resource at pharmatimes.com
Most Recently Shared on September 6, 2011 at 12:48 pm By:
U.K. watchdog didn't like 2nd-line colorectal data @PharmaTimes: NICE draft "no" to Erbitux, Avastin, Vectibix http://t.co/dwXibcs #pharma
Amgen's Vectibix fails late stage trial | InPharm
inpharm.com — “Amgen's Vectibix fails late stage trial | InPharm” View full resource at inpharm.com
Most Recently Shared on August 12, 2010 at 11:55 am By:
Pharmafocus Health News and Pharma
Amgen’s Vectibix fails late stage trial http://ht.ly/2oz0Y
Amgens Vectibix Trial Data Misses Primary Endpoint | Pharmaceutical Processing
pharmpro.com — “The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone” View full resource at pharmpro.com
Most Recently Shared on August 11, 2010 at 1:51 pm By:
RT @PharmProEditor: #Amgen's Vectibix Trial Data Misses Primary Endpoint http://bit.ly/a9P7CV
Analysis Of Vectibix(R) Study Using New Gene Technology Helps To Advance Prospects For Personalized Medicine
medicalnewstoday.com — “Amgen (Nasdaq: AMGN) announced detailed results from a new biomarker analysis of the pivotal Phase 3 408 trial of Vectibix® (panitumumab) plus best supportive care (BSC) compared to BSC alon” View full resource at medicalnewstoday.com
Most Recently Shared on April 22, 2010 at 3:08 pm By:
Analysis Of Vectibix(R) Study Using New Gene Technology Helps To Advance Prospects For Personalized Medicine http://mnt.to/3BBz #genetics
Phase 3 study of Vectibix for the treatment of metastatic colorectal cancer (mCRC) - MPR
empr.com — “Amgen announced results from its Phase 3 studies of Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC).” View full resource at empr.com
Most Recently Shared on October 7, 2010 at 9:54 pm By:
MPR News: Phase 3 study of Vectibix for the treatment of metastatic colorectal cancer (mCRC): Amgen announced resu... http://bit.ly/9qpMYN
Vectibix(R) In Combination With Chemotherapy Significantly Improves Progression-Free Survival In Second-Line Metastatic Colorectal Cancer
medicalnewstoday.com — “Amgen (Nasdaq: AMGN) announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-lin” View full resource at medicalnewstoday.com
Most Recently Shared on September 23, 2009 at 12:17 pm By:
MNT Clinical Trials Health News
Vectibix(R) In Combination With Chemotherapy Significantly Improves Progression-Free Survival In Second-Line Met.. http://bit.ly/1OcVFd
Vectibix(R) In Combination With Chemotherapy Significantly Improves Progression-Free Survival In First-Line Metastatic Colorectal Cancer
medicalnewstoday.com — “Amgen (Nasdaq: AMGN) announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the” View full resource at medicalnewstoday.com
Most Recently Shared on September 25, 2009 at 12:54 pm By:
MNT Clinical Trials Health News
Vectibix(R) In Combination With Chemotherapy Significantly Improves Progression-Free Survival In First-Line Met.. http://bit.ly/12AhEO
ImClone and Bristol-Myers's Erbitux and Amgen's Vectibix Label Change Approved for KRAS Gene - Health Blog - WSJ
blogs.wsj.com — “Patients with mutations to the KRAS gene won't benefit from these medicines.” View full resource at blogs.wsj.com
Most Recently Shared on July 20, 2009 at 2:47 pm By:
Erbitux, Vectibix Label Change Approved for KRAS Gene http://bit.ly/bXIJ4
Amgen Announces Top-Line Results Of Phase 3 Head And Neck Cancer Trial
medicalnewstoday.com — “Amgen (Nasdaq: AMGN) announced top-line results from a randomized Phase 3 trial evaluating Vectibix® (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squam” View full resource at medicalnewstoday.com
Most Recently Shared on August 12, 2010 at 2:00 pm By:
MNT Ear, Nose Throat Health News
Amgen Announces Top-Line Results Of Phase 3 Head And Neck Cancer Trial http://mnt.to/3HhG #entnews
Test predicts effects of Amgen cancer drug | Reuters
reuters.com — “WASHINGTON (Reuters) - Researchers at Amgen found more mutations that show who will not be helped by its colon cancer drug Vectibix and said on Sunday the study shows companies can find efficient ways” View full resource at reuters.com
Most Recently Shared on April 18, 2010 at 10:57 pm By:
Test predicts effects of Amgen cancer drug http://link.reuters.com/sen38j
Test predicts effects of Amgen cancer drug | Reuters
reuters.com — “WASHINGTON (Reuters) - Researchers at Amgen found more mutations that show who will not be helped by its colon cancer drug Vectibix and said on Sunday the study shows companies can find efficient ways” View full resource at reuters.com
Most Recently Shared on April 18, 2010 at 10:53 pm By:
HealthIT Policy Health News and Health IT
Test predicts effects of Amgen cancer drug: WASHINGTON (Reuters) - Researchers at Amgen found more mutations that ... http://bit.ly/a9WFZY
Test predicts effects of Amgen cancer drug | Reuters
reuters.com — “WASHINGTON (Reuters) - Researchers at Amgen found more mutations that show who will not be helped by its colon cancer drug Vectibix and said on Sunday the study shows companies can find efficient ways” View full resource at reuters.com
Most Recently Shared on April 18, 2010 at 10:53 pm By:
Test predicts effects of Amgen cancer drug: WASHINGTON (Reuters) - Researchers at Amgen found more mu... http://bit.ly/9hBCrU #health #news
Amgen Announces Top-Line Results Of Phase 3 Head And Neck Cancer Trial - QualityPoint Technologies
qualitypointtech.net — “Amgen (Nasdaq: AMGN) announced top-line results from a randomized Phase 3 trial evaluating Vectibix (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone [median 11.1 months versus 9.0 months, hazard ratio 0.87 (95% CI: 0.73, 1.0” View full resource at qualitypointtech.net
Most Recently Shared on August 12, 2010 at 1:51 pm By:
Amgen Announces Top-Line Results Of Phase 3 Head And Neck Cancer Trial: Amgen (Nasdaq: AMGN) announced top-line re... http://bit.ly/9nbRMm
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
FiercePharma
FiercePharma's 140. Join 50,000 pharma insiders on our free newsletter at FiercePharma.com
Advertisement
